[HTML][HTML] Leukemic stem cells and therapy resistance in acute myeloid leukemia
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
Amino acid depletion therapies: starving cancer cells to death
M Butler, LT van der Meer, FN van Leeuwen - Trends in Endocrinology & …, 2021 - cell.com
Targeting tumor cell metabolism is an attractive form of therapy, as it may enhance treatment
response in therapy resistant cancers as well as mitigate treatment-related toxicities by …
response in therapy resistant cancers as well as mitigate treatment-related toxicities by …
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells
Venetoclax with azacitidine (ven/aza) has emerged as a promising treatment regimen for
acute myeloid leukemia (AML), with a high percentage of clinical remissions in newly …
acute myeloid leukemia (AML), with a high percentage of clinical remissions in newly …
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
EM Cherry, D Abbott, M Amaya, C McMahon… - Blood …, 2021 - ashpublications.org
Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …
second most common form of acute leukemia in children. Despite this, very little …
Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy
D Forte, M García-Fernández, A Sanchez-Aguilera… - Cell metabolism, 2020 - cell.com
Like normal hematopoietic stem cells, leukemic stem cells depend on their bone marrow
(BM) microenvironment for survival, but the underlying mechanisms remain largely …
(BM) microenvironment for survival, but the underlying mechanisms remain largely …
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
APR-246 is a promising new therapeutic agent that targets p53 mutated proteins in
myelodysplastic syndromes and in acute myeloid leukemia (AML). APR-246 reactivates the …
myelodysplastic syndromes and in acute myeloid leukemia (AML). APR-246 reactivates the …
Metabolic dysregulation contributes to the progression of Alzheimer's disease
X Yan, Y Hu, B Wang, S Wang, X Zhang - Frontiers in neuroscience, 2020 - frontiersin.org
Alzheimer's disease (AD) is an incurable neurodegenerative disease. Numerous studies
have demonstrated a critical role for dysregulated glucose metabolism in its pathogenesis …
have demonstrated a critical role for dysregulated glucose metabolism in its pathogenesis …
Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction
The mechanism of action of eprenetapopt (APR-246, PRIMA-1MET) as an anticancer agent
remains unresolved, although the clinical development of eprenetapopt focuses on its …
remains unresolved, although the clinical development of eprenetapopt focuses on its …
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia
Therapy resistance represents a major clinical challenge in acute myeloid leukemia (AML).
Here we define a 'MitoScore'signature, which identifies high mitochondrial oxidative …
Here we define a 'MitoScore'signature, which identifies high mitochondrial oxidative …